Literature DB >> 15961557

Dopamine, dopamine D2 receptor short isoform, transforming growth factor (TGF)-beta1, and TGF-beta type II receptor interact to inhibit the growth of pituitary lactotropes.

D K Sarkar1, K Chaturvedi, S Oomizu, N I Boyadjieva, C P Chen.   

Abstract

The neurotransmitter dopamine is known to inhibit prolactin secretion and the proliferation of lactotropes in the pituitary gland. In this study, we determined whether dopamine and TGFbeta1 interact to regulate lactotropic cell proliferation. We found that dopamine and the dopamine agonist bromocriptine stimulated TGFbeta1 secretion and TGFbeta1 mRNA expression but inhibited lactotropic cell proliferation both in vivo and in vitro. The dopamine's inhibitory action on lactotropic cell proliferation was blocked by a TGFbeta1-neutralizing antibody. We also found that PR1 cells, which express low amounts of the dopamine D2 receptor, demonstrated reduced expression of TGFbeta1 type II receptor and TGFbeta1 mRNA levels and had undetectable levels of TGFbeta1 protein. These cells showed a reduced TGFbeta1 growth-inhibitory response. Constitutive expression of the D2 receptor short isoform, but not the D2 receptor long isoform, induced TGFbeta1 and TGFbeta1 type II receptor gene expression and recovered dopamine- and TGFbeta1-induced growth inhibition in PR1 cells. The constitutive expression of D2 receptor short isoform also reduced the tumor cell growth rate. These data suggest that a TGFbeta1 system may mediate, in part, the growth-inhibitory action of dopamine on lactotropes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15961557      PMCID: PMC2872191          DOI: 10.1210/en.2005-0430

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  42 in total

Review 1.  Mammalian membrane-bound adenylyl cyclases.

Authors:  R Taussig; A G Gilman
Journal:  J Biol Chem       Date:  1995-01-06       Impact factor: 5.157

2.  Damage to hypothalamic dopaminergic neurons is associated with development of prolactin-secreting pituitary tumors.

Authors:  D K Sarkar; P E Gottschall; J Meites
Journal:  Science       Date:  1982-11-12       Impact factor: 47.728

3.  Agonist-induced desensitization of D2 dopamine receptors in human Y-79 retinoblastoma cells.

Authors:  A C Barton; L E Black; D R Sibley
Journal:  Mol Pharmacol       Date:  1991-05       Impact factor: 4.436

4.  Effects of bromocriptine on hormone production and cell growth in cultured rat pituitary cells.

Authors:  P W Johansen; E Haug; K M Gautvik
Journal:  Acta Endocrinol (Copenh)       Date:  1985-10

5.  Characterization of the mouse transforming growth factor-beta 1 promoter and activation by the Ha-ras oncogene.

Authors:  A G Geiser; S J Kim; A B Roberts; M B Sporn
Journal:  Mol Cell Biol       Date:  1991-01       Impact factor: 4.272

6.  Contemporary therapy of prolactin-secreting adenomas.

Authors:  D Tonner; J Schlechte
Journal:  Am J Med Sci       Date:  1993-12       Impact factor: 2.378

7.  Transforming growth factor-beta 1 messenger RNA and protein expression in the pituitary gland: its action on prolactin secretion and lactotropic growth.

Authors:  D K Sarkar; K H Kim; S Minami
Journal:  Mol Endocrinol       Date:  1992-11

8.  Dopamine inhibits prolactin secretion stimulated by the calcium channel agonist Bay-K-8644 through a pertussis toxin-sensitive G protein in anterior pituitary cells.

Authors:  A Enjalbert; F Musset; C Chénard; M Priam; C Kordon; S Heisler
Journal:  Endocrinology       Date:  1988-07       Impact factor: 4.736

9.  Pharmacological characterization of the D2 dopamine receptor negatively coupled with adenylate cyclase in rat anterior pituitary.

Authors:  A Enjalbert; J Bockaert
Journal:  Mol Pharmacol       Date:  1983-05       Impact factor: 4.436

10.  Transient removal of dopamine potentiates the stimulation of prolactin release by TRH but not VIP: stimulation via Ca2+/protein kinase C pathway.

Authors:  G Martínez de la Escalera; J Guthrie; R I Weiner
Journal:  Neuroendocrinology       Date:  1988-01       Impact factor: 4.914

View more
  13 in total

1.  Persistent ERK/MAPK activation promotes lactotrope differentiation and diminishes tumorigenic phenotype.

Authors:  Allyson Booth; Tammy Trudeau; Crystal Gomez; M Scott Lucia; Arthur Gutierrez-Hartmann
Journal:  Mol Endocrinol       Date:  2014-12

Review 2.  Genesis of prolactinomas: studies using estrogen-treated animals.

Authors:  Dipak K Sarkar
Journal:  Front Horm Res       Date:  2006       Impact factor: 2.606

3.  Sex differences in the pituitary transforming growth factor-β1 system: studies in a model of resistant prolactinomas.

Authors:  M Victoria Recouvreux; Lara Lapyckyj; M Andrea Camilletti; M Clara Guida; Ana Ornstein; Daniel B Rifkin; Damasia Becu-Villalobos; Graciela Díaz-Torga
Journal:  Endocrinology       Date:  2013-09-05       Impact factor: 4.736

Review 4.  The pituitary TGFβ1 system as a novel target for the treatment of resistant prolactinomas.

Authors:  M Victoria Recouvreux; M Andrea Camilletti; Daniel B Rifkin; Graciela Díaz-Torga
Journal:  J Endocrinol       Date:  2015-12-23       Impact factor: 4.286

5.  Role of the autonomic nervous system in rat liver regeneration.

Authors:  Cunshuan Xu; Xinsheng Zhang; Gaiping Wang; Cuifang Chang; Lianxing Zhang; Qiuyan Cheng; Ailing Lu
Journal:  Cell Mol Neurobiol       Date:  2011-01-25       Impact factor: 5.046

6.  Active and total transforming growth factor-β1 are differentially regulated by dopamine and estradiol in the pituitary.

Authors:  M Victoria Recouvreux; M Clara Guida; Daniel B Rifkin; Damasia Becu-Villalobos; Graciela Díaz-Torga
Journal:  Endocrinology       Date:  2011-04-26       Impact factor: 4.736

7.  The Balance of PI3K and ERK Signaling Is Dysregulated in Prolactinoma and Modulated by Dopamine.

Authors:  Allyson K Roof; Siwanon Jirawatnotai; Tammy Trudeau; Crystal Kuzyk; Margaret E Wierman; Hiroaki Kiyokawa; Arthur Gutierrez-Hartmann
Journal:  Endocrinology       Date:  2018-06-01       Impact factor: 4.736

8.  Pituitary volume in schizophrenia spectrum disorders.

Authors:  F Romo-Nava; W S Hoogenboom; P E Pelavin; J L Alvarado; L H Bobrow; F P Macmaster; M Keshavan; R W McCarley; M E Shenton
Journal:  Schizophr Res       Date:  2013-03-19       Impact factor: 4.939

9.  Effects of TGFbeta1 on gene expression in the HP75 human pituitary tumor cell line identified by gene expression profiling.

Authors:  Katharina H Ruebel; Alexey A Leontovich; Yoshinori Tanizaki; Long Jin; Gail A Stilling; Shuya Zhang; Kendra Coonse; Bernd W Scheithauer; Matilde Lombardero; Kalman Kovacs; Ricardo V Lloyd
Journal:  Endocrine       Date:  2008-04-10       Impact factor: 3.633

10.  Roles of dopamine 2 receptor isoforms and g proteins in ethanol regulated prolactin synthesis and lactotropic cell proliferation.

Authors:  Amitabha Sengupta; Dipak K Sarkar
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.